Report updated Apr 23, 2026

Overview · Full Intel report in progress

Amplatzer™ Portfolio is an established medical app that is completely free. With a 5.0/5 rating from 16 reviews, it shows polarized user reception.

What is Amplatzer™ Portfolio?

The Amplatzer™ Portfolio app by Abbott is a clinical support tool designed to assist medical professionals in selecting appropriate structural intervention devices. By inputting defect information derived from imaging, users receive device recommendations based on official Instructions for Use (IFU).

Current Momentum

v3.3 · 6mo ago

Maintenance

Last updated 183d ago. 5 versions tracked.

AI-powered deep analysis surfacing high-signal insights. Still in beta, accuracy improves daily. For informational purposes only.

Competition

Rivals identification in progress

7-Day Rank Pulse 🇺🇸

Medical

No ranking data

MedicalGrossing

Rating Pulse 🇺🇸

What makes this app unique?

What Does It Look Like?

How Is The App's Momentum Right Now?

Loading...

What Are The Key Features?

Device Suggestion EngineStandard

Suggests applicable Amplatzer™ devices based on user-inputted defect information from imaging.

Regional AvailabilityStandard

Displays the specific portfolio of devices available within the user's designated region.

Offline FunctionalityStandard

Provides full access to device information and recommendations without requiring an active internet connection.

Cross-Platform CompatibilityStandard

Optimized for use on both smartphones and tablets to support clinical workflows.

How much does it cost?

Free

Who Built It?

Abbott

(1.4K)

Providing integrated digital interfaces for medical devices and metabolic health tracking to improve patient outcomes and clinical data access.

Portfolio

13

Apps

Free 12
Medical58%
Business25%
Lifestyle8%

Who is Abbott?

Abbott occupies a specialized position where mobile software serves as a critical, regulated interface for proprietary medical hardware, such as cardiac monitors and neurostimulators. Their moat is built on deep clinical integration and regulatory clearances that are difficult for pure-play software competitors to replicate. The recent launch of Lingo marks a strategic expansion into the consumer biowearable market, testing whether their clinical credibility can capture the broader metabolic health category.

Who is Abbott for?

  • Patients with implanted cardiac or neuromodulation devices
  • Medical professionals performing structural heart interventions
  • Health-conscious consumers
Active

Portfolio momentum

The publisher released 7 updates in the last 6 months, with a major release occurring just 2 days ago, indicating high current development focus on their active titles.

Last release · 2d agoActive apps · 4Abandoned · 5

Analysis in progress, available soon

What do users think recently?

Analysis in progress, available soon

Analysis in progress, available soon

What is the competitive landscape for Amplatzer™ Portfolio?

How's The Medical Market?

Market outlook for this category

Available very soon

Strategic analysis coming soon

SWOT, key takeaways & outlook

The outtake for Amplatzer™ Portfolio

Key Takeaways

This app serves as a mobile reference tool to streamline the selection of Abbott structural intervention devices based on clinical imaging data.

Where Is It Heading?

Trend analysis

Available very soon

Disclosure

Independent intel to help builders create better apps.

AI-powered analysis with editorial review, built from publicly available sources. See methodology.

Marlvel.ai is not affiliated with, endorsed by, or sponsored by Amplatzer™ Portfolio, its developer, the app publisher, Apple, or Google Play. All trademarks, logos, and screenshots referenced remain the property of their respective owners.

Hope this helps & keep building! · Found an error?

What's new in this report

No changes detected yet.

Cite this report

Marlvel.ai. “Amplatzer™ Portfolio Intelligence Report.” Updated Apr 23, 2026. https://marlvel.ai/intel-report/medical/amplatzer-portfolio

Agent Markdown (.md)·

Data licensed under CC-BY-NC 4.0